Comments on: Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease

Comments on: Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease https://www.novumpr.nl/2016/12/07/boehringer-ingelheim-hcp-survey-nearly-20-of-newly-diagnosed-lung-cancer-patients-tested-for-egfr-mutations-at-risk-of-missing-out-on-personalised-treatments-for-their-disease/?utm_source=rss&utm_medium=rss&utm_campaign=boehringer-ingelheim-hcp-survey-nearly-20-of-newly-diagnosed-lung-cancer-patients-tested-for-egfr-mutations-at-risk-of-missing-out-on-personalised-treatments-for-their-disease NovumPR press releases Wed, 07 Dec 2016 14:09:45 +0000 hourly 1 https://wordpress.org/?v=6.8.2